Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
- Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes onlyRR 2.45 [1.72, 3.49]3 studies · 464 participantsModerate